Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Evidence of micro-and macro-thrombi in the arteries and veins of critically ill COVID-19
patients and in autopsies highlight the occurrence of COVID-19-associated coagulopathy …

Background Persistent symptoms including breathlessness, fatigue, and decreased exercise
tolerance have been reported in patients after acute SARS‐CoV‐2 infection. The biological …

Background Severe coronavirus disease 2019 (COVID‐19) is characterized by an increased
risk of thromboembolic events, with evidence of microthrombosis in the lungs of deceased …

Background Consistent with fulminant endothelial cell activation, elevated plasma von
Willebrand factor (VWF) antigen levels have been reported in patients with COVID‐19. The …

The alterations in the hemostatic balance in COVID‐19 patients are strongly disturbed and
contribute to a high prothrombotic status. The high rate of venous thromboembolism in …

Objectives Thrombin generation (TG) with and without thrombomodulin (TM) was evaluated
in COVID-19 patients with different disease severity and thromboprophylaxis regimen, in …

ADAMTS13, a metalloproteinase, specifically cleaves unusually large multimers of von
Willebrand factor (VWF), newly released from vascular endothelial cells. The ratio of …

Introduction In addition to the deleterious effects Covid-19 has on the pulmonary and
cardiovascular systems, COVID-19 can also result in damage to the nervous system. This …

Background The COVID-19 pandemic has created enormous challenges for the clinical
management of patients with hematological malignancies (HMs), raising questions about …